NACDS insists that comprehensive DIR fee reform now depends on further legislative and regulatory action to improve predictability, fairness, and viability for pharmacies.
Importantly, the potential COVID-19 funding agreement that had been discussed prior to the two-week Congressional recess did not include funding for programs for the uninsured.
Darren Herring (left), district director for U.S. Rep. Trent Kelly (R-MS), participated in a Kroger pharmacy tour in Tupelo, MS, where he met with Kroger pharmacy team member Greg Wood (right). To engage your company in the NACDS RxIMPACT Pharmacy Tour Program, please contact Heidi Ecker at Hecker@nacds.org. | Photo Credit: Kroger
NACDS commends the members for their active role in prioritizing the health and wellbeing of the American people — including the nation’s most vulnerable.
NACDS continues to urge collaboration across the Biden Administration and the U.S. Congress to help ensure allocation of funding for the Health Resources and Services Administration (HRSA) Uninsured Program, Coverage Assistance Fund (CAF) Program, testing programs and other essential COVID-19 care programs for COVID-19 vaccinations, testing and treatment.
NACDS President and CEO Steven C. Anderson issued the following statement today related to the introduction of bipartisan legislation in the U.S. House of Representatives that would help ensure the continuity of accessible pharmacy-based care:
Groups applaud CMS’ ongoing efforts to address DIR fees; urge further action for comprehensive pharmacy DIR reform that “reduce[s] [Medicare] beneficiary drug costs and also protect[s] pharmacy access”.
NACDS urges Biden Administration to ensure clarity or to act decisively to extend PREP Act authorities that have served Americans well, and that Americans do not want to see rolled back.
NACDS comment letter to Biden Administration urges CMS to finalize proposal, implement regulatory guardrails and standardized pharmacy measures that best serve Medicare patients and help protect pharmacy viability.
On Wednesday, March 2, the Oversight and Investigations Subcommittee of the U.S. House of Representatives Energy and Commerce Committee held a hearing titled, “Lessons from the Frontline: COVID-19’s Impact on American Health Care.”
